Locations:
SearchReducing risk of recurrence 70%
Poly (ADP-ribose) polymerase (PARP) inhibitors block the repair of damaged DNA in cancer cells, increasing cell death.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In 2018, the FDA approved the first PARP inhibitor as a maintenance therapy after first-line chemotherapy in women with BRCA gene mutations. More recently, study results linked PARP inhibitors with a 70% reduction in risk of ovarian cancer recurrence.
In this video, learn more about why PARP inhibitors for maintenance therapy in ovarian cancer are one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients